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SHORT REPORTS
Sclerosing Encapsulating Peritonitis:
A Case Successfully Treated with
Immunosuppression
Sclerosing encapsulating peritonitis (SEP) associ-
ated with peritoneal dialysis (PD) has been reported
frequently since its initial description by Gandhi in
1980 (1). The etiology remains elusive: peritonitis
might be the most important risk factor, but acetate-
based dialysis solutions, chlorhexidine as a disinfec-
tant, and β−blocking drugs have also been implicated
as causative agents.
Sclerosing encapsulating peritonitis, a particular
presentation of sclerosing peritonitis (SP) should be
distinguished from simple peritoneal sclerosis (SS). The
latter is almost always present, in variable degrees, in
PD patients for more than a few months and leads to a
deterioration of membrane permeability. Bioincom-
patibility of solutions and time on PD are its presumed
etiological factors. Usually, SEP presents as small bowel
obstruction, malnutrition, sometimes with blood-
stained dialysate, and is characterized by cocooning of
the small bowel by a very thick fibrous sheath, often
with sparse calcified plates lining the peritoneum.
The mean SP incidence in recently published stud-
ies ranged between 3.5 (2) and 4.2/1000 patients/year
(3). Sclerosing encapsulating peritonitis is a severe
complication, although rare, with a mortality rate
exceeding 60%, due to sepsis and malnutrition. The
treatment is still debated: surgical management is
difficult and frequently leads to fatal bowel perfora-
tion. Immunosuppressive agents have been associated
with some success, supporting the hypothesis that
SEP could be immunologically mediated.
We report a clinical case of a continuous ambula-
tory peritoneal dialysis (CAPD) patient, with clinical
and radiological signs of SEP, successfully treated with
prednisone and azathioprine, parenteral nutrition,
and transfer to hemodialysis (HD). She recovered from
the intestinal obstruction and remains asymptomatic
18 months later.
CLINICAL REPORT
The patient is a female Caucasian, born in Novem-
ber of 1975, with juvenile nephronophthisis. She began
HD in May 1984. In March 1985 she had her first
cadaveric kidney transplant (CKT), with immediate
function but it failed 4 months later because of non-
compliance. A definitive vascular access was not pos-
sible and she was transferred to CAPD with a
lactate-based solution. She had two peritonitis episodes
by unknown agents before her second CKT in October
1986. This graft had excellent function, but was com-
plicated with ureteral necrosis, which was surgically
resolved, and one corticosensitive acute rejection. She
recovered and her Tenckhoff catheter was removed
5 months later. In June 1993 a late rejection, again
due to noncompliance, subsided. A second Tenckhoff
catheter was introduced and she returned to CAPD,
with some residual renal function, in November 1994
using four bags per day of a lactate-based solution,
glucose 1.36%, calcium 1.25 mmol/L Baxter system.
In February 1995 she had a new Staphylococcus
epidermidis uncomplicated peritonitis. She had a third
CKT in May 1995, complicated by immediate vascu-
lar thrombosis and graft infarction; she remained on
CAPD. In July 1995, she had another uncomplicated
S. epidermidis peritonitis. Following this incident, she
needed one 3.86% glucose dialysis per day to main-
tain adequate ultrafiltration (UF). She became hyper-
sensitized, with a panel-reactive antigen of 84%. In
January 1996, a peritoneal equilibration test (Twar-
dowski method) showed a low-average transport with
a 4-hour dialysate-to-plasma ratio (D/P) creatinine of
0.54, similar to that of 1 year before (0.58).
During 1996, there were three new peritonitis epi-
sodes (one Streptococcus viridans and two S. epi-
dermidis) which promptly resolved. In December
1996, acute rejection episodes on stopping steroids
led to transplantectomy (second graft). Hemoperito-
neum without peritonitis persisted for 3 days. Since
then, she has needed one 2.27% and one 3.86% bag
per day. On 6 February 1997, she was admitted with
a new peritonitis episode, which was treated with van-
comycin and ceftazidime. A methicillin-sensitive
S. epidermidis was identified and treatment was
changed to cefazolin. Severe abdominal pain and fever
persisted, and the peritoneal catheter was substituted
6 days later. On 18 February 1997, with persisting
fever and abdominal complaints, Candida parap-
silosis was detected in the culture of the catheter tip
and in a new sample of peritoneal effluent. Abdomi-
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nal ultrasonography (US) showed no collections and
was interpreted as normal. The patient was treated
with intraperitoneal fluconazole for 2 days, then
changed to intravenous amphotericin B. She was
transferred to HD, with intradialytic nutritional
supplementation. The Tenckhoff catheter stayed in
place for 5 more days, maintaining peritoneal
washings. Her fever disappeared but her abdominal
pain increased severely, relieved only by opioids, and
obstructive symptoms, nausea, vomiting, and malnu-
trition with an 8-kg weight loss developed. A new US
was interpreted as normal.
On 10 March 1997, an abdominal computed tomog-
raphy (CT) showed intestinal adhesions and the bowel
abnormally restricted to the central part of the abdo-
men, peritoneal thickening, and loculation of the ab-
dominal cavity (Figure 1). The typical cocoon image
emerged and allowed the diagnosis of SEP. Total
parenteral nutrition, epidural analgesia, and immu-
nosuppression with azathioprine 50 mg/day plus pred-
nisone 100 mg/day were prescribed. Surgical
management was discussed but not done owing to the
unsatisfactory results previously reported. Three days
later complaints diminished, epidural analgesia could
be stopped and 10 days later she started progressive
oral nutrition with intradialytic parenteral supple-
mentation for 1 month more. A follow-up CT scan
performed on 18 March 1997 showed some improve-
ment. Azathioprine was stopped at 2.5 months of
treatment and steroids were continued for 2 months
more with progressive tapering without relapse of
pain or occlusion. She remains on HD using a central
catheter. The patient recovered her lost weight and
had a serum albumin of 3.7 g/dL. A last CT performed
in August 1997 showed normal distribution of the
bowel; the “cocoon” had disappeared (Figure 2).
DISCUSSION
With the increasing number of PD patients and
the increasing survival on PD, SP becomes an impor-
tant problem. An Australian study (3) showed a near
exponential increase in SP incidence with time on PD:
from 1.9% for patients on dialysis less than 2 years,
to 6.4%, 10.8%, and 19.4% for more than 5, 6, and 8
years, respectively, suggesting the duration of the
exposure of the peritoneum to PD to be a major risk
factor. However, some cases occur early in the course
of PD.
Peritoneal sclerosis has two distinct forms: the SS
form — thought mainly dependent on the bio-
incompatibility of the solutions — with a sclerotic
submesothelial layer not exceeding 40 μ, and without
significant inflammatory infiltrate (4); and the SP form
where there is a dramatic progression of the sclerosis
after an inflammatory insult, such as peritonitis. The
thickness of the sclerotic tissue reaches much higher
values  (1000 – 4000 μ) than in SS, and a marked
chronic inflammatory infiltrate is invariably present
(4). Although bioincompatibility is a risk factor, a de-
finitive etiology for SEP is still unknown. Peritonitis
is the most commonly invoked, but not obligatory,
pathogenic factor. The underlying process of SP may
be immunological. A particular form of SP, SEP (en-
capsulating form), is characterized by bowel obstruc-
tion due to the extensive fibrosis covering and enclosing
the gut like a rigid bag. The case we described pre-
sented the clinical and radiological features of SEP.
The image of a cocoon bowel observed on CT, based on
a suggestive clinical presentation, was diagnostic (2,3)
and we considered peritoneal biopsy too risky.
This patient was on PD for 42 months and had an
incidence of peritonitis of 2.6 episodes/year, much
higher than our mean incidence of 0.7 episodes/pt/
year. The impact of peritonitis on mesothelial cells,
and on their intrinsic fibrinolytic activity are well
known. After this damage, the multipotential stem
cells of the subserosa may differentiate as mesothe-
lial cells, causing a new epitheliation of the perito-
Figure 2 — Abdominal computed tomography image
5 months after Figure 1, showing normal distribution of
the bowel loops, filling of all the cavity, with lumenal patency.
Figure 1 — Abdominal computed tomography image at time
of diagnosis of sclerosing encapsulating peritonitis, showing
adherent bowel loops, with posterior tethering and lumenal
narrowing, peritoneal thickening, and loculated fluid.
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neum or, to the contrary, leading to fibroneogenesis
and peritoneal sclerosis. This process of regeneration
versus fibrosis is affected not only by the number and
duration of peritonitis episodes, but also by their char-
acteristics: persisting peritonitis (2), late peritonitis
of a previously damaged peritoneum (2), and the se-
verity of the last peritonitis (2). More aggressive
agents such as S. aureus, Pseudomonas, and fungi are
more likely to damage the peritoneum. The increased
fibrinous exudate due to increased coagulability and
decreased fibrinolysis justifies the decision of some
authors, including these authors, to maintain the cath-
eter in place for 48 hours, if possible, to maintain peri-
toneal washing. The fact that two of three SP cases
present after transfer from PD suggests that PD helps
to remove fibrin accretion (3).
Peritonitis is only one of many risk factors for SP
(3). The peritonitis rate has decreased in the past
10 years and, on the contrary, SP has progressively
increased: from 1.5/1000 in the past decade, to 4.2/
1000 (3) in the first half of the present decade. In many
cases, a previous peritonitis episode could not be docu-
mented, which suggests other factors are implicated
in SP genesis.
The number of abdominal surgeries, related or not
to the catheter, might be another risk factor (2,5). The
use of acetate-based PD solution in the early 1980s
was undoubtedly related with SP process. Chlor-
hexidine and β-blocking agents have also been respon-
sible for a considerable number of SP cases. Peritoneal
exposure to glucose, hypertonicity, low pH, plasticiz-
ers, glucose degradation products (GDP) by heat ster-
ilization, and even trauma from the tip of the catheter
(5), have all been implicated as risk factors (2,3). Some
antimicrobial agents administered intraperitoneally
are likely to negatively affect re-epithelization of the
peritoneum. Our patient received fluconazole intra-
peritoneally for 3 days, as proposed by peritonitis
treatment recommendations, although there is little
experience with this route of administration. We do
not know if it contributed to the SP; however, small
bowel obstructive symptoms appeared before its use.
Some authors consider UF failure as an alerting sign
for PS, and suggest systematic screening for SP in pa-
tients on PD for more than 4 – 5 years who present
loss of UF (5). Peritoneal effluent CA125 may also be a
sign. Our patient presented UF deterioration.
Imaging of the abdominal cavity became progres-
sively more important during the present decade for
the diagnosis of SEP. Abdominal x ray is of low utility
(5). Ultrasonography can show peritoneal thickening
and a preperitoneal membrane, forming the typical
image of trilayer membrane or “sandwich-like” mem-
brane, and a fixed and dilated bowel (5). The CT is
the most useful method for this diagnosis (2,3,5). The
characteristic image of a cocoon, with the small bowel
restricted to the central part of the abdomen due to
the fibrotic sheath covering and closing the loops, and
the resulting contracted mesentery, peritoneal thick-
ening, calcifications, and the septa leading to fluid
loculation are the features often seen on CT (2,3,5),
and were present in our patient. The colonic transit
study, although now simplified, takes 2 or 3 days to
show an increased colonic transit time (5).
Therapeutic strategy is a difficult decision. One
invariable attitude is to stop PD and oral nutrition
and transfer the patient to total parenteral nutrition
and HD. The cases diagnosed after stopping PD sug-
gest a possible causal relationship between this stop
and SP expression, and it may be advisable to main-
tain the catheter and lavage if infection can be ruled
out. Surgical adhesiolysis is invasive and difficult to
perform: to find a cleavage plane for the lysis of the
adhesions and remove the fibrotic sheath is difficult
and sometimes impossible work, especially if fibrosis
overpasses the superficial layer. Occasional intesti-
nal perforation may be fatal.
Immunosuppression is another option of therapeu-
tic strategy, as an alternative to surgery or sometimes
trying to facilitate the ensuing surgery. The improve-
ment of small bowel obstruction in some SP patients
after transplantation encouraged this strategy. Some
authors only have SP survivors among those who were
treated with immunosuppressive drugs, mostly renal
transplanted patients (6). Immunosuppressive regi-
mens were variable between reports, but all of them
had prednisone and another drug, usually azathio-
prine. This supported our decision to use these two
drugs, but the ideal prescription is not known; some
have advocated intraperitoneal prednisone alone.
When we started the immunosuppression, the fun-
gal peritonitis seemed fully treated, with microbio-
logical tests repeatedly negative, but we maintained
amphotericin for 14 days.
From the experience acquired with this case, we
believe that the therapeutic strategy adopted, which
included prednisone and azathioprine, was decisive
for the favorable outcome.
La Salete S. Martins
Anabela S. Rodrigues
António N. Cabrita
Serafim Guimaraes
Department of Nephrology
Hospital de Santo António
Porto, Portugal
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Intraperitoneal Fluconazole for Fungal
Peritonitis in CAPD: Report of Two Cases
Fungal infection accounts for between 1% and 15%
of episodes of peritonitis in patients with end-stage
renal disease managed by continuous ambulatory
peritoneal dialysis (CAPD) (1,2). Management re-
mains challenging because treatment strategies are
controversial. Even if clinical symptoms resolve, many
patients cannot resume CAPD secondary to perito-
neal fibrosis or adhesion (3). Amphotericin B
(AMPH-B) has the greatest activity of all antifungal
agents. However, this agent is extremely toxic, it does
not diffuse well into peritoneal fluid from the blood
(2), and its intraperitoneal (IP) administration is of-
ten painful and may increase the risk of peritoneal
fibrosis and adhesion (3). Fluconazole (FLCZ) is a rela-
tively nontoxic imidazole with strong activity against
yeast, and is well absorbed when given either orally
or intravenously (4,5). Some authors have reported
that the likelihood of peritoneal adhesions after
completion of therapy may be decreased by oral FLCZ
(6,7), and it is now widely used as a first-line agent
against fungal peritonitis.
However, not all patients given FLCZ have a good
outcome. Michel et al. (8) reported that catheter re-
placement after FLCZ treatment failed because of
peritoneal adhesions in one of two cases in which it
was attempted. A detailed analysis of 32 patients who
received FLCZ treatment demonstrated that only 4
were able to continue CAPD successfully without in-
terruption. Eleven of 26 patients who were managed
with catheter removal were transferred to hemodi-
alysis, and there were four deaths.
Dahl et al. (9) recently investigated the pharmaco-
kinetic characteristics of IP FLCZ in patients under-
going continuous cycling peritoneal dialysis who did
not have peritonitis. They concluded that IP admin-
istration for fungal peritonitis was the preferred route,
since it allowed for outpatient treatment without the
need for vascular access, and ensured adequate IP
drug concentrations. We report the cases of 2 patients
in whom IP FLCZ was successful for fungal peritoni-
tis, and CAPD could be continued.
PATIENTS
Case 1: The first patient was a 64-year-old woman
with glomerulonephritis who began CAPD in Febru-
ary 1986. She had no history of surgery or abdominal
disease. In early January 1992, she was diagnosed
with acute tonsillitis and was given antibiotics. Nine
days later she developed a cloudy peritoneal effluent.
Upon examination, her temperature was 37.2°C and
she had diffuse abdominal tenderness. Her periph-
eral white blood cell count was 14 500/mm3. No fungi
were seen on Gram stain. We initially performed intra-
abdominal lavage with cephapirin (250 mg/L) while
continuing peritoneal dialysis. Because peritoneal
fluid cultures showed Candida albicans, treatment
with intravenous FLCZ (200 mg start; 100 mg daily)
was started on the third hospital day. The effluent
cleared within 48 hours. However, 1 day later, the di-
alysate once again became cloudy. On the sixth hos-
pital day, IP FLCZ (25 mg/L of dialysate) was started
instead of intravenous FLCZ. After 2 days the dialy-
sate became clear and no micro-organism was cul-
tured from this fluid. Intraperitoneal FLCZ was
continued for 1 week and then oral FLCZ (100 mg
daily) was administered for 2 weeks. There has been
no relapse of the infection since that time.
Case 2: The second patient was a 57-year-old man
with chronic glomerulonephritis who had been on he-
modialysis for 10 years when he elected to switch to
CAPD in January 1996. In March 1987, a cardiac pace-
maker was implanted for sick sinus syndrome. Late
in October 1996, he was diagnosed with trichophyto-
sis in his fingers. Seven days later he showed a cloudy
peritoneal effluent. Intraperitoneal lavage was per-
formed initially, using a temporary catheter as a drain-
age tube. A few lavages per day were performed using
heparinized physiological saline solution. Peritoneal
dialysis was continued without antibiotic treatment
because the patient showed no other symptoms. Three
days later he developed a low-grade fever and anor-
exia. He came to our hospital on 4 November. His pe-
ripheral WBC was 6950/mm3, and Gram stains were
negative. We performed IP lavage, while continuing
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peritoneal dialysis, with IP cefmetazole sodium
(250 mg/L of dialysate) on the first day, and intrave-
nous cefmetazole sodium (1 g daily) on the second day.
After 6 days of therapy, symptoms and signs remained
unchanged and C. albicans grew from a dialysate fun-
gal culture. Intravenous FLCZ (200 mg start, 100 mg
daily) was begun. Still the dialysate showed no im-
provement, and on the eighth day of treatment, IP
FLCZ (25 mg/L of dialysate) was started.
After 2 days, signs and symptoms remained un-
changed. The patient’s Tenckhoff catheter was removed
and replaced immediately with a temporary perito-
neal catheter. The temporary catheter was introduced
into the peritoneal cavity through the same wound. A
purse-string suture was placed around the catheter. A
culture of the first cuff and a second culture of the
Tenckhoff catheter yielded C. albicans. Hemodialysis
was started the next day via a femoral vein catheter.
Peritoneal lavage was continued twice daily using a
heparinized physiological saline solution (1000 mg/L)
with FLCZ (50 mg), which was flushed in at 1 L and
immediately drained. This was continued until the
dialysate culture was negative.
On day 28 of treatment the temporary catheter was
removed. Simultaneous serum and dialysate concen-
trations of FLCZ measured by HPLC-UV at the time
of catheter removal were 7.1 μg/mL and 20.3 μg/mL,
respectively. Although the patient complained of thirst
throughout the lavage period, there were no changes
in his blood pressure, weight, or other clinical charac-
teristics. After removal of the catheter, oral FLCZ
(100 mg daily) was continued for 3 weeks. On day 45
of therapy and after serum C-reactive protein was no
longer detected, a new indwelling Tenckhoff catheter
was placed. Subsequent cultures of the patient’s peri-
toneal fluid have shown no change, and he has suc-
cessfully resumed CAPD. The peritoneal clearance and
ultrafiltration capacity in this patient did not change
after treatment.
DISCUSSION
Fungal peritonitis is an increasingly frequent se-
rious complication of peritoneal dialysis that usually
results in catheter loss. The goals of treatment should
include eradication of infection as rapidly and as safely
as possible, in a manner that allows the patient to
continue dialysis. It is desirable that the infection is
treated successfully without withdrawal of peritoneal
dialysis as in Case 1. However, in the majority of pa-
tients, removal of the IP catheter is required, as in
Case 2.
In both cases, we initially administered intrave-
nous FLCZ after C. albicans was isolated in the peri-
toneal dialysate. Even after 2 days, signs and
symptoms remained unchanged, and so we changed
to IP FLCZ. We waited 2 days to determine efficacy
because, according to published reports in all cases
in which peritonitis was cured without catheter re-
moval, the effluent cleared within 48 hours (7,10,11).
Reported cases of fungal peritonitis treated with
FLCZ are few. Even the route of administration re-
mains controversial. Based on investigations of serum
concentrations of FLCZ, oral administration of FLCZ
seems to be quite sufficient. Oral treatment produced
adequate IP dialysate concentrations. However, the
dialysate concentration (20.3 μg/mL) of FLCZ mea-
sured in our Patient 2 was fairly high; it was over
double the concentration (2.3 – 9 μg/mL) reported by
Levine et al. (6) who administered the same dose
orally. Presuming that this high dialysate concentra-
tion was effective in Patient 1, IP administration
seems to be a method that should be tried initially.
When the infection cannot be cured with adminis-
tration of FLCZ, it is generally agreed that the
Tenckhoff catheter needs to be removed, because the
catheter is colonized with the causative fungi and it
exacerbates the infection (12,13). Nagappan et al. (14)
have reported that, in mild cases, the infection can be
eradicated by catheter removal alone. Amici et al. (15)
have stated that it is important to heighten local anti-
fungal drug concentrations and wash out inflamma-
tory and fungal debris to prevent peritoneal adhesion
after catheter removal. Keogh et al. (16) reported that
insertion of a temporary peritoneal catheter is effec-
tive for the continuation of IP lavage and IP drug ad-
ministration. They repeated peritoneal lavage
frequently for 8 – 18 days, until the fluid was micro-
biologically clear, using 0.5- to 1.0-L exchanges with
miconazole and heparin.
In our opinion, if the original catheter is removed,
a few lavages per day are enough to avoid formation
of massive peritoneal adhesions and are easy enough
even for outpatients to comply with. Therefore, we
removed the Tenckhoff catheter and inserted a tem-
porary catheter simultaneously through the same
wound in Patient 2. Then we commenced peritoneal
lavage, using a heparinized physiological saline solu-
tion (1000 mg/L) with FLCZ 50 mg, and continued it
only twice per day until the dialysate culture was
negative. Lavage by physiological saline solution
seemed to be effective in removing high dextrose in
the peritoneal liquid, since the growth of fungus is
frequently related to high concentrations of dextrose.
We suggest the following regimen:
1. Commence administration of IP FLCZ.
2. If clinical resolution is not observed after 2 days,
remove the Tenckhoff catheter and insert a tem-
porary peritoneal catheter immediately.
3. Commence peritoneal lavage with physiological
saline solution and continue administration of IP
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Methicillin Resistance Patterns
Associated with Peritonitis in a
University-Based Peritoneal
Dialysis Centera
The development of Streptococcus faecalis isolates
exhibiting vancomycin resistance has recently re-
sulted in the recommendation to avoid vancomycin
as initial empiric therapy in many clinical settings,
including treatment of peritonitis in patients on
chronic peritoneal dialysis (PD) (1–4). Many practi-
tioners have embraced this recommendation, although
some remain unconvinced (5,6). Limited clinical data
are presently available describing the outcomes in
patients with PD-associated peritonitis treated in this
manner (6–9).
We describe the antibiotic susceptibility data, spe-
cifically regarding methicillin sensitivity, for gram-
positive PD peritonitis cases, at a university center,
to facilitate additional discussion of this important
issue.
FLCZ.
4. After the causative fungi can no longer be iso-
lated, remove the temporary peritoneal catheter.
5. After no inflammation can be found (i.e., serum
C-reactive protein is undetectable), implant a new
Tenckhoff catheter.
There were no side-effects in our patients due to
FLCZ, and no further episodes of fungal peritonitis
were observed. The use of IP FLCZ as well as perito-
neal lavage with physiological saline solution after
removal of the Tenckhoff catheter allowed us to suc-
cessfully continue CAPD. This is an easy procedure.
We will continue to study this approach in the future.
Hiroshi Kameoka
Kenjirou Kumakawa
Toshimitu Matuoka
Michiko Nakano
Yasuo Shiraiwa
Osamu Yamaguchi1
Department of Urology
Jyusendo General Hospital
Koriyama City
Fukushima Medical College1
Fukushima, Japan
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M E T H O D S
All cases of peritonitis occurring in a university-
based PD program over a 5-year period were retro-
spectively identified by review of ongoing,
unit-maintained, quality assurance documents. Defi-
nition of peritonitis in our program was made clini-
cally with laboratory confirmation (white blood cell
count > 100/mm3 in dialysis effluent, with > 50% poly-
morphonucleocytes) using recommended criteria (1).
For the purpose of calculating peritonitis rates, bill-
ing records were reviewed to determine the total num-
ber of patients at risk for each time interval. Directed
chart review of patient medical records was performed
to obtain dialysate culture results and antibiotic sen-
sitivity data for each bacterial strain isolated from
dialysis effluent. Relapsing peritonitis (same organ-
ism, occurring within 30 days of completion of antibi-
otic treatment) was not counted as a new case or
bacterial isolate. Recurrent peritonitis (occurring
greater than 30 days after completion of antibiotic
course, or infection with a different organism) was
counted as a separate case.
Antibiotic sensitivities were determined by a stan-
dardized disk-diffusion method performed in the
Clinical Microbiology Laboratory of the University of
Michigan Medical Center, Ann Arbor, MI, U.S.A. Anti-
biotic susceptibility data were not available for some
Staphylococcus epidermidis isolates during a portion
of the study period because of laboratory policy, re-
sulting in missing antibiotic susceptibility data in 39
of 123 gram-positive isolates. Results are reported
with descriptive statistics only.
RESULTS
Over the 5-year period reviewed, a total of 202 epi-
sodes of peritonitis occurred during 345 patient-years
at risk, resulting in a mean peritonitis rate of 0.58 epi-
sodes per patient-year at risk (Table 1). Dialysis ef-
fluent cultures resulted in no growth in 34 of
202 cases (17%) over the study period. Dialysis cul-
ture identified 182 isolates, including 123 gram-posi-
tive organisms (68%), 51 gram-negative organisms
(28%), and 8 (4%) nonbacterial organisms. Staph.
epidermidis was the most common bacterium iso-
lated in each year and for the entire study period
(58/182 isolates, 32%).
In vitro antibiotic sensitivity data were available
for 84 of 123 gram-positive bacterial isolates (Table 2).
Overall, methicillin resistance was reported in 40%
(34/84) of gram-positive isolates over the 5-year study
period. Of the 48 S. epidermidis isolates tested for in
vitro antibiotic sensitivity, 50% (24/48) were methi-
cillin resistant, while 26% (8/31) S. aureus isolates
were reported as methicillin resistant.
DISCUSSION
Antibiotic sensitivity patterns of gram-positive
bacteria isolated from dialysate of patients with acute
peritonitis at the University of Michigan Medical
Center over a 5-year period demonstrated a signifi-
cant incidence of methicillin resistance (and presum-
ably resistance to other beta-lactam antibiotics). Of
particular concern, approximately one quarter of
S. aureus isolates demonstrated in vitro methicillin
resistance. Overall peritonitis rates and distribution
of causative organisms were consistent with previ-
ous reports from this and other centers.
Several limitations were present in our study, in-
cluding its retrospective nature, relatively small num-
bers of peritonitis cases, incomplete antibiotic
sensitivity data for S. epidermidis isolates, and the
lack of clinical outcome results. In an attempt to vali-
date our antibiotic sensitivity results for staphylococ-
cal isolates, we subsequently compared the methicillin
resistance rates from peritonitis isolates to general
resistance patterns from staphylococcal isolates re-
ported for all isolates from the University of Michi-
gan Microbiology Laboratory and found similar
methicillin resistance rates (C. Pierson, personal
communication).
Our goal in performing this study was not to add
to the literature describing clinical outcomes of PD-
associated peritonitis, but rather to document the
antibiotic resistance patterns of bacterial isolates from
a large tertiary-care medical center, with specific
emphasis on beta-lactam resistance in gram-positive
organisms. Furthermore, during the study period, our
peritonitis treatment protocol included initial intra-
peritoneal vancomycin and tobramycin, with adjust-
ment of antibiotic coverage as indicated by culture
and sensitivity results and clinical improvement. Sev-
eral studies have already been published document-
ing the efficacy of similar regimens, and our clinical
results are similar to the published experience. Our
in vitro data should be interpreted with caution how-
ever, as in vitro antibiotic sensitivity does not neces-
sarily predict clinical outcome, particularly in
PD-associated peritonitis. In this setting, high con-
centrations of antibiotic are added directly to the peri-
toneal cavity and significant changes in peritoneal
antibiotic concentration may occur, depending on the
administration scheme used (10). Furthermore, peri-
tonitis outcome is related to organism-specific factors
in addition to specific antibiotic treatment (11).
Current recommendations for treatment of PD-
related peritonitis include initial treatment with a
first-generation cephalosporin and aminoglycoside
intraperitoneally, with subsequent adjustment of an-
tibiotic regimen based on culture and sensitivity data
as well as clinical response to initial therapy (1). We-
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ber et al. reported successful treatment of PD-associ-
ated peritonitis with a regimen including continuous
intraperitoneal cefazolin and gentamicin in the set-
ting of a low-incidence of in vitro beta-lactam antibi-
otic resistance (9).
Concern over the recommendation to use cefazolin
instead of vancomycin for empiric initial treatment
has been raised, in part because of uncertainty about
the effectiveness of such regimens in treating beta-
lactam-resistant staphylococcal infections (5,12). Van
Biesen and colleagues propose that cefazolin is not
the empiric gram-positive agent of choice for all PD
centers, despite published recommendations (5). A
review of culture and susceptibility data in their cen-
ter revealed that a widely recommended protocol
using cefazolin and gentamicin would cover only 78%
of peritonitis episodes, assuming that in vitro sensi-
tivity data predict clinical outcome. Based on these
data, this group devised a new protocol using vanco-
mycin and gentamicin initially, then oral ciprofloxacin
for ambulatory patients. Intraperitoneal ceftazidime
and ciprofloxacin are used in patients requiring hos-
pitalization. With this protocol, an in vitro coverage
rate of 96% is predicted.
Clinical experience with intermittent cefazolin for
treatment of peritonitis in situations where increas-
ing beta-lactam resistance is present have been mixed.
Lai et al. reported a gram-positive response rate of
95% with a regimen of cefazolin 500 mg/L and gen-
tamicin 20 mg/L, once daily, in 19 peritonitis episodes
(7). In a retrospective study of 55 patients, Vas et al.
compared vancomycin 2 g weekly plus tobramycin
60 mg daily against cefazolin 1.5 g daily plus
tobramycin 60 mg daily in the treatment of PD-asso-
ciated peritonitis. There was no significant difference
in overall efficacy between the regimens, with a suc-
cess rate of 74% and 77%, respectively. However, the
cefazolin/tobramycin regimen resolved only 45% of
episodes due to methicillin-resistant coagulase-nega-
tive staphylococcal infections, while the vancomycin/
tobramycin regimen resolved 73% (8). In a retrospec-
tive examination of 118 cases of gram-positive peri-
tonitis in 85 patients, Alves and Dantas reported that
vancomycin was twice as effective as cefazolin when
used as first-line therapy for S. aureus, despite high
antibiotic sensitivity to cephalosporins (6).
Although micro-organisms are generally consid-
ered resistant to cefazolin when the minimum inhibi-
tory concentration (MIC) is > 64 mg/L, the high
concentrations used in continuous intraperitoneal (IP)
dosing (cefazolin 125 mg/L) may be sufficient to over-
come this “apparent resistance.” In contrast, an inter-
mittent once-daily cefazolin dose may not achieve
sustained peritoneal concentrations high enough to
TABLE 1
Peritonitis Data and Dialysate Culture Results
Patients Peritonitis Culture-negative Bacterial isolates
at risk episodes Peritonitis peritonitis Bacterial isolates
Year (n) (n) ratea (n) (n) Gram+:gram–:other
1993 75 41 0.55 7 36 26:10:0
1994 76 54 0.71 12 44 32:12:0
1995 65 49 0.75 8 43 28:13:2
1996 65 31 0.48 6 30 18:9:3
1997 64 27 0.42 1 29 19:7:3
Total 345 202 0.586b 34 182 123:51:8
a Peritonitis episodes per patient-year at risk.
b Mean peritonitis rate over study period.
TABLE 2
In Vitro Methicillin Resistance of Gram-Positive Organisms
Coagulase-negative Coagulase-positive Other gram-positive
staphylococci staphylococci organisms Annual total
Year (%) (%) (%) (%)
1993 5/10 (50) 1/9 (11) 0/0 (0) 6/19 (32)
1994 5/12 (42) 1/5 (20) 0/0 (0) 6/17 (35)
1995 4/12 (33) 3/8 (38) 1/1 (100) 8/21 (38)
1996 5/6 (83) 1/2 (50) 1/2 (50) 7/10 (70)
1997 5/8 (63) 2/7 (29) 0/2 (0) 7/17 (41)
Total 24/48 (50) 8/31 (26) 2/5 (40) 34/84 (40)
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Effect of Erythropoietin Therapy on
Serum Apolipoprotein A1 Levels in
Patients Undergoing Chronic
Peritoneal Dialysis
Recombinant human erythropoietin (EPO) is
widely used in the treatment of anemia in patients
on peritoneal dialysis (PD) (1,2). Erythropoietin treat-
ment increases food intake and improves tissue oxy-
genation, protein metabolism, glucose utilization, and
insulin resistance. All these factors may influence lipid
metabolism in PD patients. In the literature, there
are only a few but conflicting reports on the effects of
EPO on the lipid profile in hemodialysis (HD) (3–10),
and fewer still in PD (4,5,9) patients. The current
study assesses the changes in the lipid profile associ-
ated with EPO treatment in PD patients.
PATIENTS AND METHODS
Nineteen patients (6 women aged 47 – 75 years,
13 men aged 26 – 74 years) undergoing standard PD
with EPO therapy from 1 to 38 months were retro-
treat these “apparently resistant” micro-organisms
(10). For this reason, the Ad Hoc Advisory Committee
for the Management of Peritonitis advises that a first-
generation cephalosporin be administered IP, continu-
ously rather than intermittently (1). Unfortunately,
to date no studies have been performed to specifically
test the effectiveness of continuous IP cefazolin
against methicillin-resistant organisms.
Empiric initial treatment of peritonitis is currently
the subject of great debate and variable clinical prac-
tice. Appropriate concern over the widespread use of
vancomycin and the emergence of vancomycin-resis-
tant bacterial strains has been raised. On the other
hand, it remains unclear whether replacement of van-
comycin by cephalosporins in treatment of PD-asso-
ciated peritonitis is prudent, especially in centers with
a high prevalence of beta-lactam-resistant gram-posi-
tive organisms. The question will best be answered
by adequately-sized, prospective, randomized clinical
trials. Until the results of such studies are available,
we remain concerned about the possible consequences
to our patients of current recommendations to avoid
initial vancomycin use in PD-associated peritonitis.
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spectively analyzed. Eight patients were diabetics.
None of the patients suffered from nephrotic syn-
drome, thyroid or liver disease, or iron deficiency or
were receiving lipid lowering drugs. In patients stud-
ied repeatedly, the factors that may affect hematocrit
and lead to changes in EPO therapy, such as an un-
derlying inflammation, changes in iron, nutritional
state, and hydration were not found. The clinical
characteristics are shown in Table 1 and the results
of lipid profile analyzed as previously reported (11)
are shown in Table 2.
In order to evaluate the relationship between EPO
doses and serum concentrations of lipids and lipopro-
teins, and to exclude (or diminish) the effect of Hct
changes on these parameters, the latter were adjusted
to Hct by the formula (serum concentration of lipid) ×
(1 – Hct) (13).
Data were evaluated by Student’s t-test, analysis
of variance, and linear regression and are presented
as mean ±SEM. Paired t-test was used for paired data.
The Mann–Whitney test and Spearman’s r were used
for assessment of lipoprotein (a).
RESULTS
As expected, patients with diabetes mellitus exhib-
ited significantly higher basal serum concentrations
of glucose than did nondiabetic patients (Table 1). The
other parameters compared (Table 1), including ab-
normal serum concentrations of lipids and lipopro-
TABLE 2
Lipid Profile (No Adjustment to Hematocrit) of Studied Patients
Groups Reference intervala Total Nondiabetics Diabetics
Triglycerides (mg/dL) <160 225.6±21.5 225.2±26.2 226.2±38.4
Total cholesterol (mg/dL) <200 246.2±10.9 241.4±14.2 252.7±18.0
LDL cholesterol (mg/dL) <130 161.2±8.0 156.1±11.3 168.1+11.4
HDL cholesterol (mg/dL) >35 39.9±2.7 40.2±13.6 39.5±3.7
Lipoprotein(a) (mg/dL) 0–30 70.1±17.5 52.5±13.0 94.4±37.3
Apolipoprotein A1 (mg/dL) 119–240 126.6±7.3 118.6±8.5 137.7±12.3
Apolipoprotein B (mg/dL) 52–163 144.1±9.8 142.8±9.6 145.5±20.2
Mean ±SE. To convert triglycerides to mmol/L, multiply by 0.01129. To convert total cholesterol, LDL-, and HDL-cholesterol
to mmol/L, multiply by 0.02586. To convert lipoprotein(a), apolipoprotein A1, and apolipoprotein B to g/L, multiply by 0.01.
a From Ref. 12.
TABLE 1
Clinical Characteristics of Studied Patients
Groups Total Nondiabetics Diabetics
Number of patients 19 11 8
Women/men 6/13 5/6 1/7
Age (years) 58.3±2.6 58.9±4.1 57.6±2.7
Lean body mass (%) 60.1±2.8 60.6±2.8 59.6±5.9
Body mass index (kg/m2) 23.8±0.7 23.3±3.1 24.6±1.4
Time on dialysis (months) 13.4±2.6 15.0±3.5 11.2±4.1
Residual renal function (mL/min) 2.1±0.6 1.3±0.4 3.5±1.3
Kt/V 2.1±0.1 2.0±0.1 2.1±0.2
Normalized protein catabolic rate (g/kg/24 hr) 1.1±0.0 1.0±0.0 1.2±0.1
Serum β2-microglobulin (mg/L) 24.8±1.8 27.6±2.1 21.0±2.7
Serum glucose (mg/dL) 129.6±14.2 98.0±5.0 173.0±26.7a
Serum albumin (g/L) 38.4±1.3 39.9±1.6 36.3±2.0
Peritoneal β2-microglobulin clearance (mL/min) 1.1±0.1 0.9±0.0 1.2±0.2
Peritoneal albumin clearance (mL/min) 0.1±0.0 0.1±0.0 0.1±0.0
Hemoglobin (g/L)b 116.2±4.3 118.6±0.6 113.0±4.3
Erythropoietin (U/kg/wk) 83.5±14.5 64.8±18.9 98.7±22.4
Mean ±SE. To convert residual renal function values to mL/s multiply by 0.01667. To convert glucose values to mmol/L
multiply by 0.05551.
a p < 0.05 versus nondiabetics.
b Hematocrit (%) = 0.36 + 0.29 hemoglobin (g/L); r = 0.959, p < 0.0001, n = 19.
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teins (Table 2) did not differ significantly between the
two subgroups (diabetics and nondiabetics). There-
fore, we analyzed the results of both subgroups to-
gether. As shown in Figure 1(a), a significant positive
correlation was observed between weekly subcutane-
ous EPO doses and serum concentrations of apolipo-
protein A1 (ApoA1). When serum concentrations of
ApoA1 were corrected for Hct, the correlation coeffi-
cient improved [Figure 1(b)]. Since the EPO effect
could obviously be mediated via its effect on hemo-
globin, we compared ApoA1 levels with hemoglobin
and Hct [Figures 1(c), 1(d)]. It can be seen that these
parameters were not significantly correlated. In ad-
dition, ApoA1 levels were positively correlated with
high-density lipoprotein (HDL)-cholesterol, residual
renal function, and Kt/V (0.05 > p < 0.09). Moreover,
the multivariate stepwise analyses (not shown)
showed that the dose of EPO was a stronger indepen-
dent determinant of serum ApoA1 concentrations
than any other factor examined (see Table 1 and
Table 2). No effect of EPO treatment on other lipids
or lipoproteins was found (results not shown). Serum
concentrations of glucose correlated significantly with
total cholesterol (TC), triglycerides (TG), and apolipo-
protein B (ApoB) (not shown).
In some patients studied repeatedly (n = 6), we
found that increases in the dose of EPO were associ-
ated with increases in serum concentrations of ApoA1
(Figure 2), and decreases in the dose of EPO (n = 3)
were associated with decreases in serum concentra-
tions of ApoA1 (not shown).
DISCUSSION
The present study demonstrates that long-term
EPO treatment (up to 38 months) significantly im-
proves ApoA1 levels in PD patients. This beneficial
effect of EPO treatment on serum ApoA1 levels in PD
patients has not been previously reported. Viron et al.
(4) assessed 5 PD and 7 HD patients receiving EPO
for 6 months. They found no changes in the lipid pat-
tern in PD patients. Pollock et al. (5) also found no
changes in lipid profile, including ApoA1, in 31 patients
on PD treated with EPO for 3 to 18 months. However,
these authors demonstrated a significant fall in TC,
TG, low-density lipoprotein-cholesterol (LDL-C), and
Figure 1 — Relationship between serum apolipoprotein A1 levels and weekly subcutaneous doses of erythropoietin (a,b),
blood values of hematocrit (c), and hemoglobin (d) in 19 patients on peritoneal dialysis, serum apolipoprotein A1 levels
adjusted to hematocrit (b) (13).
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ApoB when the results of lipid and lipoprotein changes
in PD and HD patients were assessed together. Mak
(9) documented normalization of plasma concentra-
tions of TG, TC, and LDL-C in 12 adolescents (6 pa-
tients on continuous cycling PD and 6 patients on
regular HD) after correction of their anemia by EPO,
at a mean interval of 6 months. This improvement in
lipid profile was associated with reversed insulin re-
sistance (9). These results corroborate the findings of
Borissova et al. (14) and Allegra et al. (6) that also show
an improvement in insulin sensitivity in HD patients
after EPO treatment. Insulin resistance is a well-
known complication of uremia (15) and may, in part,
contribute to the abnormal lipid profile in dialysis
patients. In the present study, serum concentrations
of glucose correlated significantly with TC, TG, and
ApoB as further evidence of insulin resistance. How-
ever, no effect of EPO treatment on lipids and lipopro-
teins, other than ApoA1, was found.
Hematocrit is a strong confounding variable of lipo-
protein measurement, especially in plasma (13), and
is strongly affected by EPO. In the present study the
improvement in the ApoA1 profile related to EPO
treatment could not be explained by the changes in
Hct. First, there was no significant correlation be-
tween Hct and ApoA1 levels. Second, both measured
and Hct-adjusted ApoA1 levels were significantly cor-
related to EPO (Figure 1). Moreover, the multivari-
ate stepwise analyses selected EPO as a stronger
independent determinant of serum ApoA1 concentra-
tions. An increase in Hct due to EPO treatment could
potentially influence peritoneal transport of small
solutes and macromolecules, including peritoneal loss
of ApoA1. In the present study, in agreement with
the results of Burkart et al. (16), we found no changes
in peritoneal transport characteristics in relation to
EPO dose changes. Therefore, the increase in the
serum concentrations of ApoA1 could not be explained
by the differences in peritoneal transport of solutes
and water induced by EPO. Alternatively, the decrease
in insulin resistance and, probably, increase in he-
patic synthesis of ApoA1 associated with EPO treat-
ment may account for the elevated ApoA1 levels in
PD patients.
Figure 2 — Individual changes in weekly subcutaneous erythropoietin doses and serum concentrations of apolipoprotein
A1 (no adjustment to Hct) in patients on peritoneal dialysis: A and B are time intervals (months; mean ±SE) such that A =
9.3 ± 2.7 versus B = 26.6 ± 3.4, p < 0.05 by paired t-test. Subcutaneous erythropoietin doses (U/kg/week; mean ±SE): A =
59.8 ± 14.9 versus B = 85.9 ± 19.1, p < 0.05 by paired t-test. Serum apolipoprotein A1 concentrations (mg/dL; mean ±SE):
A = 95.7 ± 5.8 versus B = 108.6 ± 4.7, p < 0.05 by paired t-test.
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Several studies in the HD population have showed
a significant increase in serum ApoA1 concentrations
during long-term EPO treatment (4,6,8,10), suggest-
ing that EPO treatment is responsible for this im-
provement. We have extended this observation to
patients undergoing PD, in whom serum ApoA1 con-
centrations were positively correlated with subcuta-
neous weekly EPO doses.
In summary, long-term EPO therapy seems to in-
crease the serum concentrations of ApoA1 in PD pa-
tients. ApoA1, a major apolipoprotein of HDL, is
generally accepted as a protective factor for coronary
artery disease (CAD): ApoA1 is associated with sever-
ity of coronary damage (17). However, a possible rela-
tionship between degree of CAD and increasing ApoA1
levels after EPO treatment in PD patients remains to
be studied in a larger population of PD patients.
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